22 research outputs found
Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme
Therapy options at the time of recurrence of glioblastoma multiforme are often limited. We investigated whether treatment with a new intratumoral thermotherapy procedure using magnetic nanoparticles improves survival outcome. In a single-arm study in two centers, 66 patients (59 with recurrent glioblastoma) received neuronavigationally controlled intratumoral instillation of an aqueous dispersion of iron-oxide (magnetite) nanoparticles and subsequent heating of the particles in an alternating magnetic field. Treatment was combined with fractionated stereotactic radiotherapy. A median dose of 30 Gy using a fractionation of 5 × 2 Gy/week was applied. The primary study endpoint was overall survival following diagnosis of first tumor recurrence (OS-2), while the secondary endpoint was overall survival after primary tumor diagnosis (OS-1). Survival times were calculated using the Kaplan–Meier method. Analyses were by intention to treat. The median overall survival from diagnosis of the first tumor recurrence among the 59 patients with recurrent glioblastoma was 13.4 months (95% CI: 10.6–16.2 months). Median OS-1 was 23.2 months while the median time interval between primary diagnosis and first tumor recurrence was 8.0 months. Only tumor volume at study entry was significantly correlated with ensuing survival (P < 0.01). No other variables predicting longer survival could be determined. The side effects of the new therapeutic approach were moderate, and no serious complications were observed. Thermotherapy using magnetic nanoparticles in conjunction with a reduced radiation dose is safe and effective and leads to longer OS-2 compared to conventional therapies in the treatment of recurrent glioblastoma
Die neuroprotektiven Effekte einer kontinuierlichen Noradrenalininfusion nach Controlled Cortical Impact Injury (CCII) beruhen zumindest zum Teil auf der verstärkten Expression glialer Glutamattransporter und einer erhöhten extrazellulären Glutamataufnahme
Tumor growth analysis by magnetic resonance imaging of the C6 glioblastoma model with prospects for the assessment of magnetohyperthermia therapy
In vivo assessment of hepatotoxicity, nephrotoxicity and biodistribution using 3-aminopropyltriethoxysilane-coated magnetic nanoparticles (APTS-MNPs) in ICR mice
PACAP as a Potential Biomarker: Alterations of PACAP Levels in Human Physiological and Pathological Conditions
Posttraumatic Administration of Pituitary Adenylate Cyclase Activating Polypeptide in Central Fluid Percussion Injury in Rats
Several in vitro and in vivo experiments have
demonstrated the neuroprotective effects of pituitary
adenylate cyclase activating polypeptide
(PACAP) in focal cerebral ischemia, Parkinson's
disease and traumatic brain injury (TBI). The
aim of the present study was to analyze the effect
of PACAP administration on diffuse axonal
injury (DAI), an important contributor to morbidity
and mortality associated with TBI, in a
central fluid percussion (CFP) model of TBI.
Rats were subjected to moderate (2 Atm) CFP
injury. Thirty min after injury, 100 μg PACAP
was administered intracerebroventricularly.
DAI was assessed by immunohistochemical
detection of β-amyloid precursor protein, indicating
impaired axoplasmic transport, and
RMO-14 antibody, representing foci of cytoskeletal
alterations (neurofilament compaction),
both considered classical markers of axonal
damage. Analysis of damaged, immunoreactive
axonal profiles revealed significant axonal protection
in the PACAP-treated versus vehicletreated
animals in the corticospinal tract, as far
as traumatically induced disturbance of axoplasmic
transport and cytoskeletal alteration were
considered. Similarly to our former observations
in an impact acceleration model of diffuse TBI,
the present study demonstrated that PACAP
also inhibits DAI in the CFP injury model. The
finding indicates that PACAP and derivates can
be considered potential candidates for further
experimental studies, or purportedly for clinical
trials in the therapy of TBI